Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00508586 | PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer | PHASE1 | COMPLETED | 33 | — | — | Nov 1, 2007 | Mar 1, 2012 | Mar 3, 2016 | 3 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | PTC299 with an aromatase inhibitor |
| Name | Type | Description |
|---|---|---|
| PTC299 | DRUG | PTC299 orally administered twice per day given in combination with anastrozole (Arimidex®), letrazole (Femara®), or exemestane (Aromasin®) |
Major Eligibility Criteria: 1. Female sex. 2. Age ≥18 years. 3. Body weight 40-100 kg. 4. ECOG performance status of 0 or 1. 5. Histologically or cytologically confirmed adenocarcinoma of the breast. 6. Presence of metastatic disease not amenable to surgery, radiation therapy, or chemoradiotherapy ...